Scorpius Holdings was selected as a member of the Biomedical Advanced Research and Development Authority’s (BARDA) Rapid Response Partnership Vehicle (RRPV). The RRPV supports BARDA in its mission to accelerate the development of medical countermeasures (MCMs) to address emerging biological threats such as pandemic influenza, infectious diseases, and other public health emergencies.
Scorpius, a CDMO, will collaborate with BARDA and other federal partners to support MCM product and technology development in critical areas such as vaccines and therapeutics. Scorpius’ capabilities in biomanufacturing and its production facilities should position it to meet the evolving needs of government agencies tasked with responding to biological threats, according to Jeff Wolf, the company’s CEO.
“This opportunity allows us to leverage our manufacturing capabilities to support BARDA, the U.S. government, and groups that service the U.S. government in rapidly addressing public health emergencies,” said Wolf. “Our team is committed to accelerating the development of medical countermeasures and delivering scalable solutions to protect public health and national security.”
Scorpius’ facilities are equipped to handle the production of biological products, offering both standard and custom solutions for the development of biopharmaceuticals, continued Wolf, adding that the company’s manufacturing platform is designed for flexibility, enabling swift responses to emerging health threats.
BARDA, a division of the U.S. Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response (ASPR), works to support the development of medical countermeasures such as vaccines, drugs, and diagnostic tools to counteract health security threat.
